Drugs / PepCan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03821272 | Nov 2019 → Feb 2025 | head and neck cancer | University of Arkansas | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PepCan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03821272 ↗ |
| Modality | Vaccine | “This is a Phase I/II study to evaluate the efficacy and safety of an HPV therapeutic vaccine called PepCan (HPV-16 E6 peptides) in adults over a two (2) year period.” NCT03821272 ↗ |
| Route | Other | “50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities” NCT03821272 ↗ |